Opexa Therapeutics Reveals Positive Top-Line Data In Phase I/II ...
RTT News - Williamsville,NY,USA
In the one-year, 8-subject extension clinical trial of relapsing remitting and secondary progressive subjects, Tovaxin therapy was shown to be safe and ...
See all stories on this topic

IntercontinentalExchange Urges CBOT Members To Reject Proposed ...
RTT News - Williamsville,NY,USA
Tovaxin therapy achieved a 92% reduction in annualized relapse rate in patients who received two treatment doses of Tovaxin eight weeks apart and were ...
See all stories on this topic

Opexa Cites Positive Tovaxin Results
Houston Chronicle - United States
... Opexa Therapeutics Inc. said Thursday it saw positive results from an early-to-mid stage study on its prospective multiple sclerosis treatment Tovaxin. ...
See all stories on this topic

Genmab to start Phase III studies of HuMax-CD20 in rheumatoid ...
Forbes - NY,USA
Genmab said the group also plans to expand the development programme through a Phase II study in relapsing remitting multiple sclerosis (RRMS) in the first ...
See all stories on this topic

Genmab Announces Development Plans for Ofatumumab
netPR.pl (komunikaty prasowe) - Poland
Ofatumumab is currently in late stage development for chronic lymphocytic leukemia (CLL), follicular non-Hodgkin's lymphoma (NHL) and in Phase II for ...
See all stories on this topic

Genmab's ofatumumab to go into Phase III for rheumatoid arthritis
Pharma Times (subscription) - London,UK
The decision comes after the firm presented data from a Phase II study of HuMax-CD20 (ofatumumab) at the European League Against Rheumatism congress in ...
See all stories on this topic

Top 20 advisors: Ken Kam boosts Elan
Blogging Stocks - USA
However, I'd note that the majority of Biogen's sales comes from Avonex, a multiple sclerosis drug that competes with Tysabri. Biogen gets 50% of Tysabri ...
See all stories on this topic

Multiple Sclerosis: The History of a Disease
RedNova Thu, 21 Jun 2007 5:24 AM PDT
By Garmany, George Multiple Sclerosis: The History of a Disease T. JOCK MURRAY, OC, MD Multiple sclerosis is not a new disease. Neither are efforts to explain and control it. Dr. T.

Tracing MS From Childhood to Adulthood
WebMD Wed, 20 Jun 2007 3:35 PM PDT
Multiple sclerosis (MS) is rare in children, but when it starts in childhood it may take longer to worsen, a European study shows.

Costs of disorders of the brain in Europe
News-Medical-Net Wed, 20 Jun 2007 3:34 PM PDT
In 2004 there were about 46 million cases of neurological diseases such as epilepsy, migraines, multiple sclerosis, Parkinson's disease and stroke among the 466 million inhabitants of the EU (excluding the two new members Romania and Bulgaria, but including the non-members Iceland, Norway and Switzerland).

Hematopoietic Prostaglandin D Synthase and DP^Sub 1^ Receptor Are Selectively Upregulated in Microglia and Astrocytes ...
RedNova Thu, 21 Jun 2007 5:43 AM PDT
By Mohri, Ikuko Kadoyama, Keiichi; Kanekiyo, Takahisa; Sato, Yo; Et al Abstract Prostaglandin (PG) D^sub 2^ is produced in activated microglia by the action of hematopoietic PGD synthase (HPGDS) and plays important roles in neuroinflammation.

Inflammation Is At The Origin And Progression Of Diseases Such As Diabetes Or Cancer
Medical News Today Thu, 21 Jun 2007 3:04 AM PDT
Fifteen top international specialists in this field will gather from 25-27 June for a conference entitled, "Inflammation and Chronic Disease", part of the "Barcelona BioMed" conference series organised by the Institute for Research in Biomedicine (IRB Barcelona) and the Fundaci??n BBVA. The event will be hosted by the Institut d'Estudis Catalans (IEC). [click link for full article]